Bydureon receives positive EU CHMP opinion for EXSCEL cardiovascular outcomes data

AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion on a Type-II variation update for Bydureon (exenatide extended-release), to include in the Eu https://pipelinereview.com/index.php/2018092669239/Proteins-and-Peptides/Bydureon-receives-positive-EU-CHMP-opinion-for-EXSCEL-cardiovascular-outcomes-data.html